Mayo Clinic Proceedings: Innovations, Quality & Outcomes (Aug 2021)

Deprescribing in Hospice Patients: Discontinuing Aspirin, Multivitamins, and Statins

  • Cari E. Low, MD,
  • Daniel E. Sanchez Pellecer, MD,
  • Wil L. Santivasi, MD,
  • Virginia H. Thompson, RPh,
  • Theresa Elwood, RN,
  • Ashly J. Davidson, MSN, RN,
  • Julie A. Tlusty, MSN, RN,
  • Molly A. Feely, MD,
  • Cory Ingram, MD

Journal volume & issue
Vol. 5, no. 4
pp. 721 – 726

Abstract

Read online

Objective: To facilitate deprescribing of aspirin, multivitamins, and statins in hospice patients enrolled in Mayo Clinic Hospice, Rochester, Minnesota. Patients and Methods: During the fall of 2019, we conducted a quality improvement project to improve care of Mayo Clinic Hospice patients by decreasing the percentage of patients taking aspirin, multivitamins, or statins. Project interventions included the addition of a palliative medicine fellow to the hospice interdisciplinary team, nurse education, and implementation of an evidence-based deprescribing resource tool. The resource tool included a communication framework to guide deprescribing conversations and a literature summary supporting deprescribing. The project team recorded the number of patients taking 1 of these medications by intermittently surveying the hospice census. Process and counterbalance measures were tracked with online surveys of hospice nursing staff. Results: At the start of the project, 22 of 69 patients (32%) were taking aspirin, a multivitamin, or a statin. After introduction of the deprescribing resource tool and the addition of a palliative medicine fellow to the interdisciplinary team, this was reduced to 20 of 83 patients (24%), a 24% decrease. Results appeared to be driven primarily by a reduction in multivitamin use (33% decrease). Self-reported comfort and knowledge about deprescribing improved among the hospice nursing staff, as did satisfaction in their workflow from 5.4 to 6.0 (maximum, 7). Conclusion: The addition of a dedicated team member to address medication issues and provision of an evidence-based deprescribing resource tool appear to reduce the use of unnecessary and potentially harmful medications in ambulatory hospice patients.